EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects

Kyeong Min Kim, Na-Hee Hwang, Ja-Shil Hyun, Dongyun Shin

Molecules · 2024

DOI: 10.3390/molecules29102226 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, 2024. Verfasst von Kyeong Min Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Gachon University, Hambakmoe-ro 191, Yeunsu-gu, Incheon 21935, Republic of Korea. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Associated Kinases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin receptor-associated kinase (IRAK) proteins are pivotal in interleukin-1 and Toll-like receptor-mediated signaling pathways. They play essential roles in innate immunity and inflammation. This review analyzes and discusses the physiological functions of IRAK1 and its associated diseases. IRAK1 is involved in a wide range of diseases such as dry eye, which highlights its potential as a therapeutic target under various conditions. Various IRAK1 inhibitors, including Pacritinib and Rosoxacin, show therapeutic potential against malignancies and inflammatory diseases. The covalent IRAK1 inhibitor JH-X-119-01 shows promise in B-cell lymphomas, emphasizing the significance of covalent bonds in its activity. Additionally, the emergence of selective IRAK1 degraders, such as JNJ-101, provides a novel strategy by targeting the scaffolding function of IRAK1. Thus, the evolving landscape of IRAK1-targeted approaches provides promising avenues for increasingly safe and effective therapeutic interventions for various diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-1 Receptor-Associated KinasesHumansProtein Kinase InhibitorsAnimalsInflammationSignal TransductionNeoplasms

Stichwörter der Autor:innen

degraderimmunityinhibitorinterleukin receptor-associated kinase (IRAK) proteins

Substanzen

Interleukin-1 Receptor-Associated KinasesIRAK1 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • College of Pharmacy, Gachon University, Hambakmoe-ro 191, Yeunsu-gu, Incheon 21935, Republic of Korea.

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Kim, K. M., Hwang, N. H., Hyun, J. S., & Shin, D. (2024). Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects. Molecules. https://doi.org/10.3390/molecules29102226

Vancouver

Kim KM, Hwang NH, Hyun JS, Shin D. Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects. Molecules. 2024. doi:10.3390/molecules29102226

BibTeX
@article{Kim2024,
  author = {Kim, Kyeong Min and Hwang, Na-Hee and Hyun, Ja-Shil and Shin, Dongyun},
  title = {Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29102226}
}
Kostenlos starten →